Follow us on:
Breaking News
November 26, 2025
Breaking News
Breaking News
New eBook from Contract Pharma
IQVIA_eBook_0925_ThisMonth@

AstraZeneca to Invest $2B in Maryland

 
AstraZeneca to Invest $2B in Maryland

Plans an expansion of its flagship biologics manufacturing facility in Frederick and construction of a new facility in Gaithersburg.
Read More >>

USP_Webinar_12-09-25_650x90
Headlines

Breaking News
Collaborations & Alliances

BioMed X, AbbVie Launch New Research Project Focused on Anhedonia

Researchers are invited to submit proposals for innovative research projects aimed at uncovering the entangled microcircuits and molecular targets disrupted in anhedonia.

SPONSOR

Speed & Flexibility: The New CDMO Advantage

Pharma’s future demands faster, more agile partners. See how leading CDMOs like ROIS are adapting to shifting market and regulatory needs.

Breaking News
Collaborations & Alliances

AGC Biologics Enters Gene Therapy Manufacturing Agreement with AAVantgarde

AGC Biologics to provide GMP manufacturing for AAVantgarde’s two novel candidates designed to address progressive and irreversible vision loss.

Breaking News
Trials & Filings

EU Clears Bristol Myers Squibb’s Breyanzi for Mantle Cell Lymphoma

Marks Breyanzi’s fourth indication in Europe, adding to existing approvals for several aggressive B-cell lymphomas.

SPONSOR

Next-Generation Topical Approach: A Breakthrough in Liposome-Integrated Formulations

Topical delivery is evolving. Discover how liposome-integrated formulations enhance penetration, retention & therapeutic effect.

Samsung_Webinar_12-02-25_650x250

Breaking News

Sanofi and Regeneron’s Dupixent Approved in EU

Approved as the first targeted medicine in the EU in over a decade for chronic spontaneous urticaria.

SPONSOR

Decentralized Clinical Trials Outlook

In this eBook from Contract Pharma and IQVIA, explore the importance of fine-tuning patient-centered DCT solutions with evolving site roles and perspectives in mind.

Featured Resources

Solution Content Centers SPOTLIGHT

Sofgen Pharmaceuticals

Sofgen Pharmaceuticals is an integrated softgel CDMO that offers end-to-end solutions in softgel technologies from development throughout delivery for generics, prescription drugs, OTC products and specialized nutraceuticals for companies interested in developing and launching novel products in North America, Canada and Europe. Our softgel facility located in West Palm Beach, US, specializes in the development and manufacturing of high-end softgel technologies, with specialized capabilities for hormonal products, HPCs, NMEs, and much more.